- Previous Close
28.00 - Open
28.15 - Bid --
- Ask --
- Day's Range
28.15 - 28.45 - 52 Week Range
26.50 - 40.15 - Volume
3,541 - Avg. Volume
33,145 - Market Cap (intraday)
1.33B - Beta (5Y Monthly) 0.09
- PE Ratio (TTM)
-- - EPS (TTM)
-2.14 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 13, 2021
- 1y Target Est
--
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and other products. The company provides its products for the therapeutic areas, such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, and otorhinolaryngology, as well as infectious diseases. It also offers test kits under the Actim name to detect influenza virus, fecal occult blood, acute pancreatitis, preterm or full-week delivery, and early water breaking. In addition, the company provides toothpaste, and mouth wash and gel products under the Oral7 name; and food and medical beauty maintenance products. Further, it imports and exports active pharmaceutical ingredients; and engages in the research of technologies, and pharmaceutical technologies transfer and cooperative development and improvement activities. The company was formerly known as Excelsior Enterprise Co., Ltd. and changed its name to Excelsior Biopharma Inc. in June 2003. Excelsior Biopharma Inc. was incorporated in 1988 and is headquartered in Taipei, Taiwan.
www.excelsiorgroup.com.tw--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 6496.TWO
View MorePerformance Overview: 6496.TWO
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6496.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6496.TWO
View MoreValuation Measures
Market Cap
1.33B
Enterprise Value
1.52B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.54
Price/Book (mrq)
1.34
Enterprise Value/Revenue
1.76
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-11.45%
Return on Assets (ttm)
-3.21%
Return on Equity (ttm)
-9.42%
Revenue (ttm)
861.91M
Net Income Avi to Common (ttm)
-98.7M
Diluted EPS (ttm)
-2.14
Balance Sheet and Cash Flow
Total Cash (mrq)
251.52M
Total Debt/Equity (mrq)
41.41%
Levered Free Cash Flow (ttm)
-311.04M